GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Net Change in Cash

GlobeStar Therapeutics (GlobeStar Therapeutics) Net Change in Cash : $-0.01 Mil (TTM As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is GlobeStar Therapeutics Net Change in Cash?

Net Change in Cash is calculated as the total of Cash Flow from Operations , Cash Flow from Investing, Cash Flow from Financing, and Effect of Exchange Rate Changes.

GlobeStar Therapeutics's Net Change in Cash for the three months ended in Dec. 2023 was $0.00 Mil. Its Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 was $-0.01 Mil.

GlobeStar Therapeutics Net Change in Cash Historical Data

The historical data trend for GlobeStar Therapeutics's Net Change in Cash can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

GlobeStar Therapeutics Net Change in Cash Chart

GlobeStar Therapeutics Annual Data
Trend Sep14 Sep15 Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23
Net Change in Cash
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.01 -0.02 -0.08 - -0.01

GlobeStar Therapeutics Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Net Change in Cash Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - -0.01 - - -

GlobeStar Therapeutics Net Change in Cash Calculation

GlobeStar Therapeutics's Net Change in Cash for the fiscal year that ended in Sep. 2023 is calculated as

Net Change in Cash= Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.206+0+0.199+0
=-0.01

GlobeStar Therapeutics's Net Change in Cash for the quarter that ended in Dec. 2023

Net Change in Cash=Cash Flow from Operations+Cash Flow from Investing+Cash Flow from Financing+Effect of Exchange Rate Changes
=-0.043+0+0.043+0
=0.00

Net Change in Cash for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $-0.01 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

GlobeStar Therapeutics Net Change in Cash Related Terms

Thank you for viewing the detailed overview of GlobeStar Therapeutics's Net Change in Cash provided by GuruFocus.com. Please click on the following links to see related term pages.

GlobeStar Therapeutics (GlobeStar Therapeutics) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » GlobeStar Therapeutics Corp (OTCPK:GSTC) » Definitions » Net Change in Cash
Comparable Companies
SONN PKBO SCPS AMPE DRMA PBLA SPRC ADIL INM BXRX OCSE:NOVO B VRTX REGN ASX:CSL SGEN XKRX:207940 MRNA HKSE:02269 XBRU:ARGX BNTX
Traded in Other Exchanges
N/A
Address
719 Jadewin Avenue, Richland, WA, USA, 99352
Website
https://www.globestarthera.com
GlobeStar Therapeutics Corp is a clinical-stage Pharmaceutical Company introducing a patented formulation of previously approved drugs for the treatment of Multiple Sclerosis. The company is focused on developing therapies for people with serious and life-threatening rare disorders.
Executives
James C Katzaroff director, officer: CEO 719 JADWIN AVE., RICHLAND WA 99352
William J Farley director 468 ALBERN AVE, OCEANSIDE NY 11572
Robert Chicoski officer: CFO 145 NEWTON ROAD, HAVERHILL MA 01830
Alex K Blankenship director, officer: CEO, Pres., Secr., Treas. 14001 WALDEN RD., SUITE 600, MONTGOMERY TX 77356
Brent Atwood 10 percent owner 5000 RIVERSIDE DR STE100E, IRVING TX 75039
Bruce C Badeau director 770 S. POST OAK LN., STE. 360, HOUSTON TX 77056
Robert W Fryer director 1520 ENCLAVE, # 1208, HOUSTON TX 77077
Robert Federowicz director, officer: Interim CEO & Chairman 495 GRAND BLVD., SUITE 206, MIRAMAR BEACH FL 32550